CLINICAL TRIALS PROFILE FOR CETACORT

All Clinical Trials for Cetacort

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002798 ↗	Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome	Completed	National Cancer Institute (NCI)	Phase 3	1996-08-01	Randomized phase III trial to compare the effectiveness of different chemotherapy regimens with or without bone marrow transplantation in treating children who have acute myelogenous leukemia or myelodysplastic syndrome. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known which treatment regimen is more effective for acute myelogenous leukemia or myelodysplastic syndrome
NCT00002970 ↗	506U78 in Treating Patients With Refractory Hematologic Cancer	Completed	Children's Cancer Group	Phase 2	1997-06-01	Phase II trial to study the effectiveness of 506U78 in treating patients with recurrent or refractory hematologic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
NCT00002970 ↗	506U78 in Treating Patients With Refractory Hematologic Cancer	Completed	National Cancer Institute (NCI)	Phase 2	1997-06-01	Phase II trial to study the effectiveness of 506U78 in treating patients with recurrent or refractory hematologic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
NCT00098839 ↗	Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)	Completed	National Cancer Institute (NCI)	Phase 1/Phase 2	2005-02-01	This Phase II trial is studying how well giving epratuzumab together with an established chemotherapy platform works in treating young patients with relapsed acute lymphoblastic leukemia. Monoclonal antibodies, such as epratuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing them or by stopping them from dividing. Giving monoclonal antibody therapy in combination chemotherapy may kill cancer cells more effectively.
NCT00098839 ↗	Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)	Completed	Children's Oncology Group	Phase 1/Phase 2	2005-02-01	This Phase II trial is studying how well giving epratuzumab together with an established chemotherapy platform works in treating young patients with relapsed acute lymphoblastic leukemia. Monoclonal antibodies, such as epratuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing them or by stopping them from dividing. Giving monoclonal antibody therapy in combination chemotherapy may kill cancer cells more effectively.

Clinical Trial Conditions for Cetacort

Condition Name

Condition Name for Cetacort
Intervention	Trials
T-cell Childhood Acute Lymphoblastic Leukemia	3
Recurrent Childhood Acute Lymphoblastic Leukemia	3
Acute Lymphoblastic Leukemia	2
Untreated Childhood Acute Lymphoblastic Leukemia	2

Condition MeSH

Condition MeSH for Cetacort
Intervention	Trials
Leukemia	9
Precursor Cell Lymphoblastic Leukemia-Lymphoma	7
Leukemia, Lymphoid	7
Lymphoma	4

Clinical Trial Locations for Cetacort

Trials by Country

Trials by Country for Cetacort
Location	Trials
United States	334
Canada	44
Australia	12
Puerto Rico	5
New Zealand	5

Trials by US State

Trials by US State for Cetacort
Location	Trials
New York	10
California	10
Pennsylvania	9
Ohio	9
Minnesota	9

Clinical Trial Progress for Cetacort

Clinical Trial Phase

Clinical Trial Phase for Cetacort
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	5
Phase 2	4

Clinical Trial Status

Clinical Trial Status for Cetacort
Clinical Trial Phase	Trials
Completed	6
Active, not recruiting	5
Recruiting	2

Clinical Trial Sponsors for Cetacort

Sponsor Name

Sponsor Name for Cetacort
Sponsor	Trials
National Cancer Institute (NCI)	14
Children's Oncology Group	7
Roswell Park Cancer Institute	1

Sponsor Type

Sponsor Type for Cetacort
Sponsor	Trials
NIH	14
Other	14
Industry	1

Clinical Trials, Market Analysis, and Projections for Cetacort

Introduction to Cetacort

Cetacort, a topical corticosteroid, is commonly used to treat various skin conditions such as allergies, eczema, and dermatitis. Understanding its clinical trial landscape, market dynamics, and future projections is crucial for both healthcare professionals and investors.

Clinical Trials and Development

While specific clinical trials for Cetacort itself may not be extensively detailed in recent updates, the broader context of clinical trials in the pharmaceutical industry provides valuable insights.

General Trends in Clinical Trials

The global clinical trials market is expected to grow significantly, driven by the increasing prevalence of chronic diseases. The market size is projected to increase from $61.58 billion in 2024 to $106.78 billion by 2032, at a CAGR of 7.1%[3].

Relevant Clinical Trial Updates

Although Cetacort is not mentioned in the latest clinical trial readouts from companies like Recursion, these updates highlight the rapid advancement in drug discovery and development. For instance, Recursion is expecting several clinical trial readouts within the next 18 months, including trials for conditions like Cerebral Cavernous Malformation and Neurofibromatosis Type 2. This indicates a vibrant and dynamic clinical trial landscape that could influence the development of topical corticosteroids like Cetacort[1].

Market Analysis for Corticosteroids

Market Size and Growth

The corticosteroids market, which includes products like Cetacort, was valued at $4.3 billion in 2023 and is projected to reach $6.9 billion by 2033, growing at a CAGR of 4.9% from 2024 to 2033. This growth is driven by the increasing demand for treatments of skin allergies, gastroenterology, endocrinology, and other conditions[2].

Segmentation and Distribution

The corticosteroids market is segmented by product (mineralocorticoids and glucocorticoids), route of administration (oral, inhaled, topical, injectable), and application (skin allergies, gastroenterology, endocrinology, etc.). Topical corticosteroids, such as Cetacort, are a significant segment due to their widespread use in treating skin conditions. Distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies[2].

Projections for Cetacort

Market Demand

Given the growing demand for corticosteroids, Cetacort is likely to benefit from this trend. The increasing prevalence of skin allergies and other conditions that require topical corticosteroid treatments will drive the demand for products like Cetacort.

Competitive Landscape

The market for corticosteroids is competitive, with major players like AbbVie and Astellas Pharma. However, Cetacort's position in the market can be strengthened through effective marketing, distribution strategies, and continuous improvement in formulation and delivery methods[2].

Regulatory and Safety Considerations

It is crucial to consider the regulatory and safety aspects of Cetacort. The use of topical corticosteroids must be carefully managed to avoid side effects such as adrenal gland problems, skin irritation, and other adverse reactions. Regular monitoring and adherence to medical guidelines are essential to ensure safe and effective use[4].

Future Outlook

Technological Advancements

The integration of AI and machine learning (ML) in drug discovery, as seen in companies like Recursion, could lead to more efficient and targeted development of corticosteroids. This could result in new formulations or improved delivery methods for Cetacort and similar products[1].

Global Health Trends

The global health landscape, including the rise in chronic diseases, will continue to drive the demand for effective treatments. As healthcare systems evolve, there will be a greater emphasis on preventive and therapeutic measures, which could further boost the market for corticosteroids like Cetacort.

Key Takeaways

• Growing Market: The corticosteroids market is expected to grow from $4.3 billion in 2023 to $6.9 billion by 2033.
• Clinical Trials: While specific trials for Cetacort are not detailed, the broader clinical trials market is expanding rapidly.
• Regulatory and Safety: Careful management and monitoring are necessary to avoid side effects associated with topical corticosteroids.
• Technological Advancements: AI and ML are transforming drug discovery and could improve future formulations of corticosteroids.
• Global Health Trends: Increasing prevalence of chronic diseases will drive demand for effective treatments like Cetacort.

FAQs

What is the projected growth rate of the corticosteroids market?

The corticosteroids market is projected to grow at a CAGR of 4.9% from 2024 to 2033[2].

What are the common side effects of Cetacort?

Common side effects include skin irritation, burning, itching, and potential adrenal gland problems, especially with prolonged use[4].

How does the global clinical trials market impact Cetacort?

The growing global clinical trials market indicates a dynamic and innovative environment in drug development, which could influence future improvements in corticosteroids like Cetacort[3].

What are the key distribution channels for Cetacort?

Key distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies[2].

How does AI and ML impact the development of corticosteroids?

AI and ML can enhance drug discovery by making the process more efficient and targeted, potentially leading to new formulations or improved delivery methods for corticosteroids[1].

Sources

1. Recursion Gives Guidance on Seven Clinical Readouts within ~18 Months and Partnership Updates at Their Download Day - Recursion.
2. Corticosteroids Market Size, Share, Demand | CAGR of 4.9% - Market.US.
3. Clinical Trials Market SIZE, SHARE | GROWTH REPORT [2032] - Fortune Business Insights.
4. Cetacort Advanced Patient Information - Drugs.com.
5. Sanofi Q1: robust 7% sales growth driven by ... - Sanofi.